ReviewJournal of pain research2026
Potential Roles of G Protein-Coupled Receptor 30 (GPR30) in Migraine Pathophysiology.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a highly prevalent and disabling neurological disorder with multiple hypotheses regarding its pathogenesis. G protein-coupled receptor 30 (GPR30), a member of the G protein-coupled receptor family, was once considered a membrane estrogen receptor. GPR30 is highly expressed in migraine-associated core tissues such as the trigeminal ganglion and exerts an indirect regulatory effect on the pathophysiological processes of migraine, yet there remain controversies over its specific molecular mechanisms and whether it is involved in estrogen-mediated regulation. This review systematically summarizes the latest research advances in the effects of GPR30 on the pathogenesis of migraine, with a focus on the molecular structure, ligand profile, distribution characteristics in the nervous system, related signal transduction pathways of GPR30, as well as its regulatory effects on migraine-associated neural functions. Existing studies have mainly reported the impacts of GPR30 on migraine-related signal pathways and neural functions in neurological diseases, but only verified the correlation between GPR30 and these signal pathways, with contradictory conclusions regarding its regulation of neurovascular functions. In clinical research, there is a lack of evidence from migraine-specific therapeutic clinical trials targeting GPR30, and no estrogen-related evidence chain has been established. Overall, GPR30 may serve as a potential novel target for the prevention and treatment of migraine, and the existing challenges also provide new research perspectives for the development of GPR30-targeted migraine-specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.